AREAS OF PRACTICE：

Ms. Chen joined Liu, Shen & Associates in 2020 and is qualified as patent attorney and attorney at law. She specializes in patent related matters, including drafting and prosecution of patent applications, reexamination, freedom-to-operate opinions and patent stability analysis, and focused on the fields of biochemistry, biopharmaceutical, immunotherapy, and cancer treatment.

Ms. Chen majors in drafting, prosecution and reexamination of patent applications in a variety of technical fields of biopharmaceutical, including antibody/ADC drugs, CAR-T cell immunotherapy, gene editing, gene sequencing, and vaccines, before multiple patent offices (CN, US, EP, JP, KR and others). Ms. Chen also participates in works involving IP due diligence, freedom-to-operate opinion, patent stability analysis and patent invalidation procedure.

Ms. Chen obtained the qualification as a patent attorney in 2019 and the qualification as an attorney at law in 2023.

EDUCATION & TRAINING:

2009-2013             Anhui University, biotechnology, Bachelor’s degree

2004-2006             Tsinghua University, biology, Master’s degree

RERESENTATIVE CASES:

-      Providing IP due diligence service for an investment corporation in investing two ADC related projects of a pharmaceutical company in Zhejiang (2020-2021)

-      Providing FTO analysis service for an investment corporation in investing antibody drug and therapeutic enzyme related projects of a pharmaceutical company in Zhejiang (2021)

-      Providing FTO analysis service for an investment corporation in investing T cell therapy related projects of a pharmaceutical company in Beijing (2021)

-      Providing FTO analysis service for an investment corporation in investing nucleic acid purification and amplification related projects of a biotech company in Zhejiang (2021)

-      Providing FTO analysis service for an international enterprise in investing T cell therapy related projects of a pharmaceutical company in Guangdong (2021)

-      Providing FTO analysis service for polypeptide drugs for treating diabetes of a pharmaceutical company in Shanghai (2021)

-      Providing FTO analysis service for polypeptide-conjugated drugs for treating cancers of a pharmaceutical company in Shanghai (2021)

-      Providing FTO analysis service for ADC drugs and its therapeutic use of a biopharma company in Shanghai (2022)

-      Providing FTO analysis service for a TCR product and its therapeutic use of a biotech company in Beijing (2022)

-      Providing FTO analysis service for a nucleic acid nanostructure and its use for drug delivery of a research center in Beijing (2022)

-      Providing FTO analysis service for an AAV gene therapy product of a biotech company in Chengdu (2022)

-      Providing patent stability analysis regarding a Chinese patent relating to a bifunctional molecule for a biotech company in Beijing (2023)

-      Participating in defending a detergent composition patent for Novozymes in the invalidation procedure (2024)

-      Providing FTO analysis service for a fusion protein product of a biotech company in Beijing (2024-2025)